Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Qazilbash MH, et al. Among authors: saliba rm. Biol Blood Marrow Transplant. 2008 Dec;14(12):1401-7. doi: 10.1016/j.bbmt.2008.09.019. Biol Blood Marrow Transplant. 2008. PMID: 19041063 Free PMC article. Clinical Trial.
Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1.
Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Przepiorka D, et al. Biol Blood Marrow Transplant. 2000;6(2A):190-7. doi: 10.1016/s1083-8791(00)70042-5. Biol Blood Marrow Transplant. 2000. PMID: 10816027 Free article.
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Khouri IF, et al. Among authors: saliba rm. Blood. 2001 Dec 15;98(13):3595-9. doi: 10.1182/blood.v98.13.3595. Blood. 2001. PMID: 11739162 Free article. Clinical Trial.
CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans.
Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KV. Stanzani M, et al. Among authors: saliba rm. Blood. 2004 Feb 1;103(3):1140-6. doi: 10.1182/blood-2003-06-2085. Epub 2003 Aug 7. Blood. 2004. PMID: 12907445 Free article.
163 results